December 14, 2016 — Patients undergoing magnetic resonance (MR) exams will find a relaxing environment with Toshiba ...

Cancer Targeted Technology (CTT), a privately-held Seattle-based biotechnology firm focusing on small molecules that target pivotal enzyme targets on cancer, announced a Phase I clinical trial has commenced in men with high-risk metastatic prostate cancer. In late August, the U.S. Food and Drug Administration cleared CTT’s first Investigational New Drug Application (IND) for a positron emission tomography (PET) imaging agent, CTT1057, labeled with a two-hour half life radiolabel, fluorine-18, and targeting prostate-specific membrane antigen (PSMA).

The American Society for Radiation Oncology (ASTRO) announced in November that Elekta has provided signficant financial support to RO-ILS: Radiation Oncology Incident Learning System a national patient safety initiative launched in 2014 by ASTRO and the American Association of Physicists in Medicine (AAPM). RO-ILS facilitates safer and higher quality care in radiation oncology by providing a mechanism for shared learning in a secure and non-punitive environment. It is the only medical specialty society-sponsored radiation oncology incident learning system within a federally listed Patient Safety Organization (PSO).

UCLA doctors have found what may be an earlier and easier way to diagnose chronic traumatic encephalopathy, or CTE, a disorder that is thought to affect some former football players and others with a history of repetitive brain trauma.